TheraRadar
Data updated: May 26, 2026

GATIFLOXACIN

Ophthalmology Approved 2011-08-19

Gatifloxacin is an eye drop used for patients with bacterial conjunctivitis. It helps patients with eye infections caused by specific susceptible bacteria, including various strains of Staphylococcus and Streptococcus. This medication treats the underlying bacterial cause to help resolve the condition.

Source: FDA Label • HI-TECH PHARMACAL • Quinolone Antimicrobial

How GATIFLOXACIN Works

Gatifloxacin works by acting as a quinolone antimicrobial. It targets specific aerobic gram-positive and gram-negative bacteria to clear the infection.

Source: FDA Label
6
Indications
--
Phase 3 Trials
14
Years on Market

Details

Status
None (Tentative Approval)
First Approved
2011-08-19
Routes
OPHTHALMIC
Dosage Forms
SOLUTION, SOLUTION/DROPS

GATIFLOXACIN Approval History

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
10 FDA actions from 2011 to 2021
Nov 2021 ORIGINAL
Update
Oct 2020 SUPPL
Label · Labeling
Dec 2019 SUPPL
Label · Labeling

What GATIFLOXACIN Treats

1 indications

GATIFLOXACIN is approved for 1 conditions since its original approval in 2011. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Bacterial Conjunctivitis
Source: FDA Label

GATIFLOXACIN Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 5 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to GATIFLOXACIN

3 of 7

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AZASITE
AZITHROMYCIN
1 shared
THEA PHARMA
Shared indications:
Bacterial Conjunctivitis
BESIVANCE
BESIFLOXACIN HYDROCHLORIDE
1 shared
BAUSCH AND LOMB
Shared indications:
Bacterial Conjunctivitis
CETRAXAL
CIPROFLOXACIN HYDROCHLORIDE
1 shared
LAB SALVAT
Shared indications:
Bacterial Conjunctivitis
📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT00410891 results posted 96803 (eProtocol 4384) Ph 4 completed Topical Antibiotics and Intravitreous Injections
NCT01421693 03NP Ph 4 completed Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
NCT01330355 results posted 646 Ph 3 terminated Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
NCT00824070 results posted 575 Ph 1 completed Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects
NCT00905762 608 Ph 1 completed Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GATIFLOXACIN FDA Label Details

Indications & Usage

GATIFLOXACIN is indicated for the treatment of Bacterial Conjunctivitis.

Looking for the branded version?

ZYMAXID

Full clinical data, patents, trials, and competitive landscape for gatifloxacin.

See ZYMAXID

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.